

Don L Gibbons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8312007/publications.pdf>

Version: 2024-02-01

141
papers

12,282
citations

30070

54
h-index

30087

103
g-index

148
all docs

148
docs citations

148
times ranked

18799
citing authors

#	ARTICLE	IF	CITATIONS
1	Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 702-709.	1.6	53
2	Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a037895.	6.2	24
3	The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. <i>Cancer Cell</i> , 2022, 40, 36-52.e9.	16.8	101
4	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. <i>Lung Cancer</i> , 2022, 164, 69-75.	2.0	2
5	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1327-1337.	0.8	29
6	MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression. <i>Cell Reports Medicine</i> , 2022, 3, 100506.	6.5	0
7	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, , .	2.6	2
8	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
9	Regulation of ZEB1 Function and Molecular Associations in Tumor Progression and Metastasis. <i>Cancers</i> , 2022, 14, 1864.	3.7	22
10	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 2461-2473.	7.0	9
11	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	12.8	34
12	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 172.	8.6	2
13	Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis. <i>Cells</i> , 2022, 11, 1484.	4.1	17
14	The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8 ⁺ cytotoxic T-cell response. <i>Genes and Development</i> , 2022, 36, 582-600.	5.9	9
15	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. <i>JAMA Network Open</i> , 2022, 5, e2215589.	5.9	15
16	Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. <i>Cancer Cell</i> , 2022, 40, 754-767.e6.	16.8	34
17	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021, 22, e415-e424.	2.6	10
18	A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naïve patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 383-390.	6.4	54

#	ARTICLE	IF	CITATIONS
19	AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 485-497.	3.4	32
20	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 127-139.	1.1	48
21	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. <i>Cancer Research</i> , 2021, 81, 1398-1412.	0.9	16
22	Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 590-606.	2.8	25
23	Development, characterization, and applications of multi-material stereolithography bioprinting. <i>Scientific Reports</i> , 2021, 11, 3171.	3.3	78
24	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	30.7	357
25	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. <i>Cancers</i> , 2021, 13, 1250.	3.7	7
26	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. <i>Lung Cancer</i> , 2021, 154, 76-83.	2.0	16
27	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. <i>British Journal of Cancer</i> , 2021, 125, 176-189.	6.4	21
28	Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. <i>Cell Reports</i> , 2021, 35, 109009.	6.4	18
29	A collagen glucosyltransferase drives lung adenocarcinoma progression in mice. <i>Communications Biology</i> , 2021, 4, 482.	4.4	16
30	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
31	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 601-609.	1.1	40
32	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. <i>Nature Communications</i> , 2021, 12, 2606.	12.8	41
33	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. <i>Cancer Discovery</i> , 2021, 11, 2506-2523.	9.4	68
34	p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi. <i>Science Advances</i> , 2021, 7, .	10.3	15
35	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839.	1.1	34
36	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5045.	12.8	42

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. <i>JCO Precision Oncology</i> , 2021, 5, 1241-1249.	3.0	11
38	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
39	Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	12
40	Deep learning-based prediction of the T cell receptor's antigen binding specificity. <i>Nature Machine Intelligence</i> , 2021, 3, 864-875.	16.0	99
41	A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	25
42	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1965-1976.	4.2	14
43	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2021, 14, 313-324.	1.5	17
44	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6655.	12.8	24
45	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. <i>Nature Communications</i> , 2021, 12, 7081.	12.8	16
46	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 358-366.	1.3	9
47	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 248-257.	1.1	97
48	The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. <i>Cells</i> , 2020, 9, 52.	4.1	56
49	MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs. <i>Oncogene</i> , 2020, 39, 6719-6732.	5.9	12
50	IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion. <i>Oncogene</i> , 2020, 39, 5979-5994.	5.9	25
51	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	101
52	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.	12.8	218
53	Multimomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020, 21, 271.	8.8	36
54	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33

#	ARTICLE	IF	CITATIONS
55	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. <i>Oncologist</i> , 2020, 25, e1457-e1463.	3.7	7
56	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. <i>Lung Cancer</i> , 2020, 146, 303-309.	2.0	2
57	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020, 15, 777-791.	1.1	94
58	PI4KIII ² is a therapeutic target in chromosome 1q amplified lung adenocarcinoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	41
59	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3525-3536.	7.0	22
60	¹⁸ F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1519-1534.	4.2	21
61	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. <i>Clinical Lung Cancer</i> , 2020, 21, 384-388.	2.6	11
62	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1449-1459.	1.1	109
63	Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. <i>Matrix Biology</i> , 2020, 91-92, 8-18.	3.6	34
64	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.	12.8	140
65	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. <i>American Journal of Cancer Research</i> , 2020, 10, 4464-4475.	1.4	5
66	ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. <i>Nature Communications</i> , 2019, 10, 5125.	12.8	72
67	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. <i>Cancers</i> , 2019, 11, 714.	3.7	79
68	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1021-1031.	1.1	79
69	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. <i>Cancers</i> , 2019, 11, 462.	3.7	20
70	A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 4819.	3.3	20
71	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	42
72	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 646-661.	9.4	555

#	ARTICLE	IF	CITATIONS
73	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. <i>Clinical Cancer Research</i> , 2018, 24, 2182-2193.	7.0	68
74	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 105, 1621-1626.	1.3	5
75	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 779-791.	1.1	53
76	Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. <i>Developmental Dynamics</i> , 2018, 247, 555-564.	1.8	96
77	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. <i>Oncotarget</i> , 2018, 7, e1376156.	4.6	14
78	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
79	TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. <i>Nature Communications</i> , 2018, 9, 2731.	12.8	88
80	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. <i>Cancer Discovery</i> , 2018, 8, 1156-1175.	9.4	323
81	In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. <i>Nature Communications</i> , 2018, 9, 2732.	12.8	33
82	The fibrotic tumor stroma. <i>Journal of Clinical Investigation</i> , 2018, 128, 16-25.	8.2	189
83	The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. <i>Journal of Clinical Investigation</i> , 2018, 128, 1267-1282.	8.2	48
84	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017, 5, 319-329.	3.4	25
85	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. <i>Cancer Research</i> , 2017, 77, 3870-3884.	0.9	163
86	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. <i>Scientific Reports</i> , 2017, 7, 13380.	3.3	208
87	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
88	Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	12.8	49
89	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 28575-28587.	1.8	157
90	Fibroblast-specific inhibition of TGF- β 1 signaling attenuates lung and tumor fibrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 3675-3688.	8.2	135

#	ARTICLE	IF	CITATIONS
91	The microRNA-200/Zeb1 axis regulates ECM-dependent β 1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. <i>Scientific Reports</i> , 2016, 6, 18652.	3.3	62
92	Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. <i>Oncolmmunology</i> , 2016, 5, e1234570.	4.6	23
93	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3638-3647.	1.6	140
94	A genetic cell context-dependent role for ZEB1 in lung cancer. <i>Nature Communications</i> , 2016, 7, 12231.	12.8	54
95	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1672-1682.	10.7	865
96	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	5.5	106
97	Musashi-2 (MSI2) supports TGF- β 2 signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6955-6960.	7.1	120
98	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 6278-6289.	7.0	130
99	Ultrahigh-throughput generation and characterization of cellular aggregates in laser-ablated microwells of poly(dimethylsiloxane). <i>RSC Advances</i> , 2016, 6, 8980-8991.	3.6	20
100	Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. <i>Molecular Cancer Research</i> , 2016, 14, 287-295.	3.4	150
101	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	7.0	353
102	Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1674-1686.	7.0	41
103	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2016, 22, 609-620.	7.0	388
104	Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. <i>Journal of Clinical Investigation</i> , 2016, 127, 117-131.	8.2	75
105	The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. <i>Oncolmmunology</i> , 2015, 4, e1002731.	4.6	24
106	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. <i>Nature Communications</i> , 2014, 5, 5241.	12.8	780
107	Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3550-3555.	7.1	74
108	Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. <i>International Journal of Cancer</i> , 2014, 134, 789-798.	5.1	27

#	ARTICLE	IF	CITATIONS
109	A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow. <i>Cancer Discovery</i> , 2014, 4, 991-994.	9.4	13
110	Smoking, p53 Mutation, and Lung Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 3-13.	3.4	205
111	ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. <i>Journal of Clinical Investigation</i> , 2014, 124, 2696-2708.	8.2	101
112	Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by <i>in silico</i> experiments. <i>Molecular Oncology</i> , 2013, 7, 968-975.	4.6	28
113	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 870-879.	9.4	127
114	The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. <i>Cancer Management and Research</i> , 2013, 5, 187.	1.9	117
115	Fibulin-2 Is a Driver of Malignant Progression in Lung Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e67054.	2.5	42
116	Acquisition Of Compound BCR-ABL1 Alleles As A Mechanism Of Resistance To Ponatinib In Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 853-853.	1.4	0
117	A Synthetic Matrix with Independently Tunable Biochemistry and Mechanical Properties to Study Epithelial Morphogenesis and EMT in a Lung Adenocarcinoma Model. <i>Cancer Research</i> , 2012, 72, 6013-6023.	0.9	155
118	The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. <i>Cancer</i> , 2012, 118, 293-299.	4.1	73
119	ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. <i>Journal of Clinical Investigation</i> , 2012, 122, 3170-3183.	8.2	135
120	Dysregulation of Cell Polarity Proteins Synergize with Oncogenes or the Microenvironment to Induce Invasive Behavior in Epithelial Cells. <i>PLoS ONE</i> , 2012, 7, e34343.	2.5	30
121	Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib. <i>New England Journal of Medicine</i> , 2011, 364, 947-955.	27.0	375
122	Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor β 2 Expression. <i>Molecular and Cellular Biology</i> , 2011, 31, 4270-4285.	2.3	63
123	miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1. <i>Molecular Cancer Research</i> , 2011, 9, 25-35.	3.4	166
124	Targets of the Tumor Suppressor miR-200 in Regulation of the Epithelial-Mesenchymal Transition in Cancer. <i>Cancer Research</i> , 2011, 71, 7670-7682.	0.9	126
125	The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 1373-1385.	8.2	172
126	Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma. <i>PLoS ONE</i> , 2009, 4, e5401.	2.5	65

#	ARTICLE	IF	CITATIONS
127	Distinct Biological Roles for the Notch Ligands Jagged-1 and Jagged-2. <i>Journal of Biological Chemistry</i> , 2009, 284, 17766-17774.	3.4	64
128	Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. <i>Genes and Development</i> , 2009, 23, 2140-2151.	5.9	435
129	Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CMLCP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy.. <i>Blood</i> , 2008, 112, 2114-2114.	1.4	3
130	Mutational Analysis of Chronic Myeloid Leukemia (CML) Clones Reveals Heightened BCR-ABL1 Genetic Instability and Wild-Type BCR-ABL1 Exhaustion in Patients Failing Sequential Imatinib and Dasatinib Therapy.. <i>Blood</i> , 2007, 110, 1938-1938.	1.4	4
131	Mutations within BCR-ABL1 295-312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.. <i>Blood</i> , 2007, 110, 1936-1936.	1.4	0
132	Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.. <i>Blood</i> , 2007, 110, 1952-1952.	1.4	0
133	Multistep Regulation of Membrane Insertion of the Fusion Peptide of Semliki Forest Virus. <i>Journal of Virology</i> , 2004, 78, 3312-3318.	3.4	46
134	Purification and Crystallization Reveal Two Types of Interactions of the Fusion Protein Homotrimer of Semliki Forest Virus. <i>Journal of Virology</i> , 2004, 78, 3514-3523.	3.4	22
135	Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. <i>Nature</i> , 2004, 427, 320-325.	27.8	332
136	Visualization of the Target-Membrane-Inserted Fusion Protein of Semliki Forest Virus by Combined Electron Microscopy and Crystallography. <i>Cell</i> , 2003, 114, 573-583.	28.9	101
137	The Fusion Peptide of Semliki Forest Virus Associates with Sterol-Rich Membrane Domains. <i>Journal of Virology</i> , 2002, 76, 3267-3275.	3.4	118
138	Molecular Dissection of the Semliki Forest Virus Homotrimer Reveals Two Functionally Distinct Regions of the Fusion Protein. <i>Journal of Virology</i> , 2002, 76, 1194-1205.	3.4	33
139	Ligand-induced Conformational Changes in the Apical Domain of the Chaperonin GroEL. <i>Journal of Biological Chemistry</i> , 1996, 271, 238-243.	3.4	20
140	Exposure of Hydrophobic Surfaces on the Chaperonin GroEL Oligomer by Protonation or Modification of His-401. <i>Journal of Biological Chemistry</i> , 1995, 270, 7335-7340.	3.4	18
141	Topology of the Na,K-ATPase. <i>Journal of Biological Chemistry</i> , 1995, 270, 8785-8796.	3.4	49